Fresenius Kabi and Formycon Reach Global License Agreement to Commercialise Ustekinumab Biosimilar to J&J’s Stelara®

Feb 2, 2023

Fresenius Kabi and Formycon AG announced they have reached a global license agreement to commercialise FYB202, biosimilar to Johnson & Johnson’s Stelara®. Under the agreement, Fresenius will have the exclusive commercialisation rights in key global markets, whilst Formycon will be responsible for development and registration with health authorities.

On 19 September 2022, Formycon announced that it was developing a biosimilar to Merck’s Keytruda® (pembrolizumab).

Print Page Mail Article